Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer study aims to sharpen drug testing with Real-World data

NCT ID NCT07174388

Knowledge-focused Sponsor: N-Power Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study is collecting information from 650 people with advanced lung cancer to create 'control arms' — groups that help researchers compare how well new treatments work. Participants will receive standard therapies, and their outcomes will be tracked. The goal is to make future clinical trials more efficient and accurate by using real-world data instead of always needing a separate control group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide a more accurate way to compare new treatments against real-world data, potentially speeding up drug development for lung cancer.
What could go wrong
This is an observational study, not testing a new treatment. It may not lead to direct patient benefits, and results depend on data quality and matching methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 650 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with metastatic NSCLC receiving first, second or third line NCCN recommended therapies

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. \> 18 years of age at the time of informed consent 2. Pathologically confirmed locally advanced or metastatic NSCLC 3. ECOG Performance of less than or equal to 1 within 4 weeks prior to starting index therapy. 4. Life expectancy of more than 3 months 5. Able to understand and sign informed consent 6. Evidence of measurable disease (as assessed by the Investigator) on available imaging (e.g CT, MRI, PET) \*see protocol for cohort specific inclusion criteria\* Exclusion Criteria: 1. Actively on a clinical trial of an investigational agent 2. Currently receiving active systemic therapy for another malignancy 3. Eligible for treatment with curative intent \*see protocol for cohort specific exclusion criteria\*

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    8 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bayhealth Medical Center, Kent Campus

    RECRUITING

    Dover, Delaware, 19901, United States

  • Bayhealth Medical Center- Sussex Campus

    RECRUITING

    Milford, Delaware, 19963, United States

  • Northwest Oncology and Hematology

    RECRUITING

    Barrington, Illinois, 60010, United States

  • Northwest Oncology and Hematology

    RECRUITING

    Elk Grove, Illinois, 60008, United States

  • Northwest Oncology and Hematology

    RECRUITING

    Hoffman Estates, Illinois, 60169, United States

  • Northwest Oncology and Hematology

    RECRUITING

    Rolling Meadows, Illinois, 60008, United States

  • Oncology Consultants

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • Pacific Cancer Care

    RECRUITING

    Monterey, California, 93940, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.